| A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab (NCT05277493) | Peking Union Medical College Hospital | 2022-03-30 |
| Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy (NCT05066607) | Intergroupe Francophone du Myelome | 2022-02-11 |
| Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance (NCT07585331) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2022-01-13 |
| Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease (NCT04984330) | Weill Medical College of Cornell University | 2021-12-01 |
| Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis (NCT05199337) | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 2021-11-30 |
| COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies (NCT05028374) | Barbara Ann Karmanos Cancer Institute | 2021-08-17 |
| Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis (NCT04895917) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2021-06-23 |
| Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab (NCT04270175) | Weill Medical College of Cornell University | 2021-04-14 |
| A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis (NCT04617925) | Stichting European Myeloma Network | 2021-02-26 |
| A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) (NCT04504825) | Alexion Pharmaceuticals, Inc. | 2020-08-25 |
| A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis (NCT04115956) | Oncopeptides AB | 2020-08-06 |
| Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis (NCT04392960) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2020-07-22 |
| A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis (NCT04304144) | Alexion Pharmaceuticals, Inc. | 2020-03-18 |
| A Registry of AL Amyloidosis (ReAL) (NCT04839003) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2020-02-27 |
| A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe (NCT04937777) | European Myeloma Network B.V. | 2019-04-23 |
| Ixazomib Maintenance Study in Patients With AL Amyloidosis (NCT03618537) | Memorial Sloan Kettering Cancer Center | 2018-08-02 |
| Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis (NCT03431896) | The Cleveland Clinic | 2018-02-01 |
| Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis (NCT03315026) | Memorial Sloan Kettering Cancer Center | 2017-12-14 |
| Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis (NCT03236792) | Icahn School of Medicine at Mount Sinai | 2017-06-12 |
| Daratumumab for the Treatment of Patients With AL Amyloidosis (NCT02841033) | Boston Medical Center | 2017-03-20 |
| Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis (NCT03000660) | Tufts Medical Center | 2017-01-01 |
| The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis (NCT02632786) | Prothena Biosciences Ltd. | 2016-03-01 |
| Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis (NCT02613182) | Prothena Biosciences Ltd. | 2016-02-01 |
| Quality of Life (QOL) Registry for Patients With AL Amyloidosis (NCT02574676) | Prothena Biosciences Ltd. | 2015-10-01 |
| Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib (NCT02489500) | Boston Medical Center | 2015-06-01 |
| Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis (NCT01222260) | Columbia University | 2013-01-01 |
| Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (NCT01758042) | Massachusetts General Hospital | 2012-11-01 |
| A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis (NCT01570387) | Boston Medical Center | 2012-06-01 |
| Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource (NCT01408225) | Ohio State University Comprehensive Cancer Center | 2011-03-17 |
| A Trial for Systemic Light-chain (AL) Amyloidosis (NCT01277016) | European Myeloma Network B.V. | 2011-01-01 |
| Autologous Stem Cell Transplantation for Patients With AL Amyloidosis (NCT04210791) | Nanjing University School of Medicine | 2010-07-01 |
| Allo SCT in Amyloidosis Non-interventional Study (NCT02257905) | European Society for Blood and Marrow Transplantation | 2009-12-01 |
| National Registry of Rare Kidney Diseases (NCT06065852) | UK Kidney Association | 2009-11-06 |
| Radioimmunoimaging of Light Chain (AL) Amyloidosis (NCT01815086) | University of Tennessee | 2008-12-01 |
| Radioimmunoimaging of AL Amyloidosis (NCT01409148) | University of Tennessee | 2008-11-01 |